- Boston Scientific is anticipated to report significant growth in both earnings and revenue for Q1.
- Analyst consensus suggests a notable upside potential for the stock in the coming year.
- Despite positive analyst sentiment, GuruFocus estimates indicate a potential downside based on GF Value.
Boston Scientific (NYSE: BSX) is gearing up to unveil its first-quarter financial results on April 23rd. Expectations are high, with analysts forecasting earnings per share to reach $0.67, representing a considerable 19.6% jump from the previous year. Meanwhile, revenue is projected to hit $4.57 billion, marking an 18.4% increase. Notably, Boston Scientific has consistently exceeded both earnings and revenue expectations over the past two years, bolstering investor confidence.
Wall Street Analysts Forecast
According to projections from 30 analysts, the average one-year target price for Boston Scientific Corp (BSX, Financial) stands at $116.34. This suggests a potential upside of 22.83% from its current trading price of $94.71, with the highest estimate reaching $130.00 and the lowest at $84.11. For a deeper dive into these estimates, visit the Boston Scientific Corp (BSX) Forecast page.
The consensus recommendation from 34 brokerage firms positions Boston Scientific Corp (BSX, Financial) as an "Outperform" with an average brokerage recommendation rating of 1.8. This rating scale ranges from 1, indicating a Strong Buy, to 5, signaling a Sell.
However, GuruFocus estimates bring another perspective. The anticipated GF Value for Boston Scientific Corp (BSX, Financial) over the next year is $76.94, which points to a potential downside of 18.76% from its current price of $94.71. The GF Value method assesses the stock's fair trading value based on historical trading multiples, past business growth, and future business performance estimates. For further details, visit the Boston Scientific Corp (BSX) Summary page.
